Benavent, Marta http://orcid.org/0000-0003-1268-4588
Sastre, Javier
Escobar, Ignacio García
Segura, Angel
Capdevila, Jaume
Carmona, Alberto
Sevilla, Isabel
Alonso, Teresa
Crespo, Guillermo
García, Lourdes
Canal, Neus
de la Cruz, Guillermo
Gallego, Javier
Funding for this research was provided by:
Ipsen
Article History
Received: 30 June 2020
Accepted: 22 January 2021
First Online: 30 January 2021
Ethics approval and consent to participate
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (Hospital Clínic, Barcelona, Spain; study code IPS-ANT-2015–01) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.
: Not applicable.
: The following authors have received speaker honoraria from Ipsen: M. Benavent, J. Sastre, I. García, A. Segura, J. Capdevila, A. Carmona, I. Sevilla, T. Alonso, G. Crespo, L. García, and J. Gallego. In addition, A. Segura has received speaker honoraria from Novartis. J. Capdevila has received honoraria for scientific consultancy role (speaker and advisory roles) from Novartis, Pfizer, Ipsen, Exelixis, Bayer, Eisai, Advanced Accelerator Applications, Amgen, Sanofi and Merck Serono and research support from Eisai, Novartis, Ipsen, Astrazeneca, Pfizer and Advanced Accelerator Applications. I. Sevilla has received speaker honoraria from Novartis and is an advisory board member of Novartis. N. Canal is employed by IQVIA, that has received honoraria from Ipsen for clinical research services. G. De la Cruz is employed by Ipsen.